Research programme: beta-lactamase inhibitors - VenatoRx PharmaceuticalsAlternative Names: VNRX 5119; VNRX 5133; VNRX-5113; VRNX 5363
Latest Information Update: 11 Nov 2016
At a glance
- Originator VenatoRx Pharmaceuticals
- Class Antibacterials
- Mechanism of Action Beta lactamase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gram-negative infections
Most Recent Events
- 09 Nov 2016 VenatoRx Pharmaceuticals and National Institute of Allergy and Infectious Diseases plan a first-in-human phase I trial in Healthy volunteers in USA (IV, Infusion) (NCT02955459)